News
DUBLIN, Ireland I May 23, 2025 I Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback